BR112019023130A2 - Compostos e métodos para tratamento de infecções bacterianas - Google Patents

Compostos e métodos para tratamento de infecções bacterianas Download PDF

Info

Publication number
BR112019023130A2
BR112019023130A2 BR112019023130-7A BR112019023130A BR112019023130A2 BR 112019023130 A2 BR112019023130 A2 BR 112019023130A2 BR 112019023130 A BR112019023130 A BR 112019023130A BR 112019023130 A2 BR112019023130 A2 BR 112019023130A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
bacterial infections
treating bacterial
formula
Prior art date
Application number
BR112019023130-7A
Other languages
English (en)
Inventor
Comita-Prevoir Janelle
Francois DURAND-REVILLE Thomas
Guler Satenig
Romero Jan
Sylvester Mark
Tommasi Ruben
Velez-Vega Camilo
Wu Xiaoyun
Zhang Jing
Original Assignee
Entasis Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics, Inc. filed Critical Entasis Therapeutics, Inc.
Publication of BR112019023130A2 publication Critical patent/BR112019023130A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

a presente invenção refere-se a compostos antibacterianos representados pela fórmula i, (i); ou um sal farmaceuticamente aceitável dos mesmos, em que x, y, r4, r5, e r6 são conforme definidos no presente pedido. também são fornecidas composições farmacêuticas compreendendo os compostos de fórmula i.
BR112019023130-7A 2017-05-08 2018-05-08 Compostos e métodos para tratamento de infecções bacterianas BR112019023130A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
US62/502,867 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (1)

Publication Number Publication Date
BR112019023130A2 true BR112019023130A2 (pt) 2020-05-26

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023130-7A BR112019023130A2 (pt) 2017-05-08 2018-05-08 Compostos e métodos para tratamento de infecções bacterianas

Country Status (26)

Country Link
US (1) US11046694B2 (pt)
EP (1) EP3630111B1 (pt)
JP (1) JP7058322B2 (pt)
KR (1) KR102611447B1 (pt)
CN (1) CN110709081B (pt)
AU (1) AU2018266640B2 (pt)
BR (1) BR112019023130A2 (pt)
CA (1) CA3059773A1 (pt)
DK (1) DK3630111T3 (pt)
EA (1) EA038393B1 (pt)
ES (1) ES2907858T3 (pt)
HR (1) HRP20220231T1 (pt)
HU (1) HUE057592T2 (pt)
IL (1) IL270380B (pt)
LT (1) LT3630111T (pt)
MA (1) MA48743A (pt)
MX (1) MX2019013291A (pt)
MY (1) MY201377A (pt)
PE (1) PE20200333A1 (pt)
PH (1) PH12019502509A1 (pt)
PL (1) PL3630111T3 (pt)
PT (1) PT3630111T (pt)
SG (1) SG11201909443YA (pt)
SI (1) SI3630111T1 (pt)
TW (1) TWI791018B (pt)
WO (1) WO2018208769A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018129A1 (en) 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
UA101966C2 (en) 2008-01-18 2013-05-27 Мерк Шарп Енд Доме Корп. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RU2569059C2 (ru) 2011-07-26 2015-11-20 Вокхардт Лимитед Фармацевтические композиции, содержащие бета-лактамный антибиотик, сульбактам и ингибитор бета-лактамаз
CN103687598B (zh) 2011-07-26 2016-03-16 沃克哈特有限公司 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物
CA2833241C (en) 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US9006230B2 (en) 2011-08-30 2015-04-14 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
MX349827B (es) 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2869051A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Isoxazole .beta.-lactamase inhibitors
US8916709B2 (en) * 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
BR112014029368B1 (pt) 2012-05-30 2020-10-27 Meiji Seika Pharma Co., Ltd inibidor de beta-lactamase e processo para preparar o mesmo
US20150203503A1 (en) 2012-08-25 2015-07-23 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
RU2646798C2 (ru) 2012-09-03 2018-03-07 Вокхардт Лимитед Антибактериальные композиции
WO2014122468A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
PT3221313T (pt) 2014-11-17 2019-04-15 Entasis Therapeutics Ltd Terapia combinada para tratamento de infecções bacterianas resistentes
MX2021010077A (es) 2016-09-16 2022-05-23 Entasis Therapeutics Ltd Compuestos inhibidores de beta-lactamasa.

Also Published As

Publication number Publication date
PT3630111T (pt) 2022-03-01
CA3059773A1 (en) 2018-11-15
DK3630111T3 (en) 2022-03-14
SG11201909443YA (en) 2019-11-28
CN110709081A (zh) 2020-01-17
EP3630111B1 (en) 2021-11-24
LT3630111T (lt) 2022-03-10
KR20200005586A (ko) 2020-01-15
KR102611447B1 (ko) 2023-12-06
EA038393B1 (ru) 2021-08-20
TWI791018B (zh) 2023-02-01
EP3630111A1 (en) 2020-04-08
PL3630111T3 (pl) 2022-05-23
HRP20220231T1 (hr) 2022-04-29
MA48743A (fr) 2020-04-08
AU2018266640B2 (en) 2022-03-03
MY201377A (en) 2024-02-21
ES2907858T3 (es) 2022-04-26
TW201843152A (zh) 2018-12-16
PE20200333A1 (es) 2020-02-14
JP7058322B2 (ja) 2022-04-21
IL270380B (en) 2022-06-01
CN110709081B (zh) 2023-09-22
MX2019013291A (es) 2020-01-15
JP2020519687A (ja) 2020-07-02
PH12019502509A1 (en) 2020-07-13
EA201992370A1 (ru) 2020-03-10
WO2018208769A1 (en) 2018-11-15
SI3630111T1 (sl) 2022-05-31
US20200165251A1 (en) 2020-05-28
AU2018266640A1 (en) 2019-11-07
HUE057592T2 (hu) 2022-05-28
US11046694B2 (en) 2021-06-29

Similar Documents

Publication Publication Date Title
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112018070549A2 (pt) degradantes de proteína mdm2
BR112018070859A2 (pt) degradantes da proteína de bet
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
WO2017100726A8 (en) Methods for treating huntington's disease
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
EA202090068A1 (ru) Соединения, влияющие на синтез пигмента и их применение для лечения бактериальных заболеваний
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
WO2016046260A8 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112018074985A2 (pt) composições antibacterianas
BR112019023130A2 (pt) Compostos e métodos para tratamento de infecções bacterianas
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]